Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023 : vimarsana.com

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Related Keywords

, Transforming Outcomes , Hepatocellular Carcinoma , Expert Insights , Applying Evidence , Hcc , Intermediate Stage , Systemic Therapy , Bclc Stage B , Patient Selection , Locoregional , Tace , Liver Function , Tumor Board , Phase Iii Studies , Phase 3 Studies , Criteria , Unsuitable , Atezolizumab , Bevacizumab , Response , Pfs , Os , Liver Directed Therapy , Open Label Phase Ii , Japan , Regimen , Sorafenib , Optimis , High Afp ,